These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Search MEDLINE/PubMed
Title: [Potentiation of arsenic trioxide-induced apoptosis by retinoic acid in retinoic acid sensitive and resistant HL-60 myeloid leukemia cells]. Author: Huang X. Journal: Chin Med J (Engl); 2000 Jun; 113(6):498-501. PubMed ID: 11775865. Abstract: OBJECTIVE: To study the effect of arsenic trioxide (As2O3) on non-APL acute myeloid leukemia (AML) cells and the interreactive effect between retinoic acid (RA) and As2O3. METHODS: RA-sensitive (S) and RA-resistant (R) HL-60 non-APL AML cells were used as an in vitro model. Cell number and trypan blue were used to observe cell growth and survival. Apoptosis was determined by morphological changes, using a DNA laddering assay, terminal deoxynucleotidyl transferase (TdT) fragment end labeling assay and a flow cytometry assay. RESULTS: As2O3 induced apoptosis in both HL-60S and HL-60R cells, As2O3-induced apoptosis was both time- and concentration-dependent in a therapeutically-achievable As2O3 range (0.25-4.0 mumol/L). Both all-trans retinoic acid (ATRA) and 9-cis retinoic acid (9cRA) potentiated As2O3-induced apoptosis, as measured by quantitative TdT fragment and labeling and flow cytometry assays in both HL-60S and HL-60R cells (P < 0.05, for all RA + As2O3 combinations vs As2O3 alone in both sublines). CONCLUSIONS: As2O3 may inhibit the growth of non-APL AML cells by promoting programmed cell death. RA can potentiate As2O3-induced apoptosis even in RA-resistant HL-60 cells in which the classical ATRA response pathway is repressed owing to a homozygous inactivating mutation in the retinoic acid receptor alpha. As2O3 can have clinical activity in non-APL cases of AML and the enhanced activity might result from the combined As2O3-RA therapy.[Abstract] [Full Text] [Related] [New Search]